After several PD-1xVEGF competitors forged alliances with Big Pharma players, Summit Therapeutics, the frontrunner in this hot cancer drug field, is reportedly seeking its own deal. | After several PD ...

After facing an unexpected regulatory delay last month, KalVista Pharmaceuticals has leapt into the commercial realm with the ...

With several high-profile drugmakers already lining up for manufacturing space, Fujifilm Biotechnologies is on the cusp of ...

China’s National Medical Products Administration (NMPA) has approved four new drugs developed by local biopharma companies, ...

Another BCMA-targeted agent has arrived for the treatment of multiple myeloma. | After a delay, Regeneron’s BCMA-directed ...

Just days after President Donald Trump was elected in November, AstraZeneca unvei | AstraZeneca CEO Pascal Soriot is plotting ...

Welcome to Fierce Pharma's regulatory tracker for the second half of 2025. | In this tracker, Fierce Pharma is recording the ...

Boehringer Ingelheim has breathed life into an American Lung Association campaign, providing support for a new push to ...

Generic and biosimilar specialist Sandoz is strengthening its footprint in Slovenia, pledging $440 million to set up a new ...

After taking aim at the United States’ vaccine safety reporting system earlier this year, Robert F. Kennedy Jr. | After ...

KKR sold off its 46.39% stake in J.B. Chemicals and Pharmaceuticals to Torrent Pharma after grooming the Indian drugmaker into a fast-growing business for the past five years.

Apellis and Sobi have amended their partnership agreement for paroxysmal nocturnal hemoglobinuria (PNH) treatment Empaveli, or Aspaveli as it is known in Europe.